FTIR spectroscopy of chronic venous leg ulcer exudates: an approach to spectral healing marker identification

Nicolas Cerusico a, Juan P. Aybar a, Silvana Lopez b, Silvia G. Molina b, Romina Chavez Jara a, Maria Eugenia Sesto Cabral a, Juan C. Valdez c, Aida Ben Altabef d and Alberto N. Ramos *a
aLaboratorio de Estudios Farmacéuticos y Biotecnología Farmacéutica, Instituto de Biotecnología Farmacéutica y Alimentaria (INBIOFAL), San Miguel de Tucumán, Tucumán, Argentina. E-mail: alnirave@gmail.com; Tel: +54381 4856596
bServicio de Dermatología, Hospital de Clínicas Presidente Nicolás Avellaneda, San Miguel de Tucumán, Tucumán, Argentina
cInstituto de Microbiología, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, San Miguel de Tucumán, Tucumán, Argentina
dINQUINOA-CONICET, Instituto de Química Física, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, San Miguel de Tucumán, Tucumán, Argentina

Received 24th November 2017 , Accepted 10th February 2018

First published on 13th February 2018


Chronic venous leg ulcer (CVLU) arises as a chronic venous insufficiency complication and is a major cause of morbidity throughout the world. Our hypothesis is that the CVLU exudate composition is a biochemical representation of the wound clinical state. Then, Fourier Transform Infrared (FTIR) spectroscopy could be a useful and less-invasive technique to study the clinical state of the ulcer. For this, the aim of this work was to perform a spectral characterization of the exudate from CVLU using FTIR spectroscopy to identify potential healing markers. 45 exudate samples from CVLU, 95% of the strains isolated from CVLU in planktonic and biofilm phenotypes and other related biological samples such as human plasma, serum, urine, blood cells, urea, creatinine, glucose and albumin were studied by FTIR spectroscopy. According to the vibration frequency of biomolecules’ (lipids, proteins, nucleic acids and carbohydrates) characteristic bonds in the infrared region, different spectral windows were selected and spectral areas of each window were measured. Besides, Savitzky–Golay second derivatives were obtained for all spectra and peaks from each standardized window were detected. FTIR spectroscopy allowed identification of sample types (exudate, plasma, serum, urine) as each one presents a unique relative composition and ratios range. Also, this technique could be useful to identify bacteria in the phenotypic-ulcer state and allows differentiation of whether bacteria are in the biofilm or planktonic form which is unlikely by conventional methods. In this work we found some spectral markers (areas, peaks) that allow identification of several parameters in the exudate such as (a) total cellularity, (b) inflammatory cell load, (c) bacterial load, (d) fibrin amount, and (e) inflammatory proteins. Because the measured areas or founded peaks are concentration-dependent this method could also serve to measure them. Therefore, FTIR spectroscopy could be useful to evaluate patient evolution as all these exudate parameters represent critical negative markers for wound healing.


Introduction

Fourier Transform Infrared (FTIR) spectroscopy is being increasingly used in biomedical applications with high degrees of success.1–6 Molecular bonds with an electric dipole moment that can change by atomic displacement owing to natural vibrations are IR active.7 These vibrational modes are quantitatively measurable by IR spectroscopy, providing a unique, label-free tool for studying the molecular composition and dynamics without perturbing the sample.7 FT-IR spectroscopy is a non-destructive method for the analysis of cells, tissue and fluids.1–8 However, there are no reported studies of wound fluids from Chronic Venous Leg Ulcers (CVLUs) by FT-IR spectroscopy.

CVLU arises as a chronic venous insufficiency complication and is a major cause of morbidity throughout the world,9–11 with an overall prevalence ranging up to 2% in the general population13 and median ulcer durations that range from six – eight months to decades.13

Several factors are involved in the CVLU delayed healing process: venous insufficiency degree,14 infection,9,15 inflammatory molecules,9etc. Due to all of these factors involved in the CVLU development, the correct diagnostic, prognosis and its treatment are difficult, leading CVLUs to a long non-healing state.16 Wound fluid or ulcer exudate may be used as a clinical state indicator, because its complex composition is reflex of the biochemical processes that occur on the wound bed and of its chronicity.17,18 Exudate formation results from a plasma ultrafiltrate as a local inflammation consequence influenced by the wound healing process.19 When the tissue is injured, the inflammatory process begins along with the wound-healing process.20 This promotes the affluence of inflammatory cells, such as polymorphonuclears (PMN), lymphocytes, and macrophages that are key to the removal of contaminating microorganisms and infection.17,20 The exudate has high viscosity and a high protein amount (>30 g L−1)18 and several components from serum like glucose,18 urea,18,21 creatinine,18,21 lactate and salts,18,21 and tissue inflammatory molecules such as cytokines, serine proteinase, cysteine proteinase, aspartic proteinase and matrix metalloproteinases (MMPs).12,17,19 Also, the exudate contains bacteria and biofilm components such as the extracellular polysaccharide matrix (EPS)22,23 and DNA.24 Therefore, the exudate might be considered as a negative healing factor in chronic wounds because the excessively proteolytic environment will continually degrade key growth promoting agents and thus will not allow normal wound healing to occur.17 Chronic wound exudate has higher MMP levels than acute exudate which causes tissue digestion.17 There is a correlation between the elevated levels of MMPs and delayed healing.12,25 Also, MMP may cause inhibition of endothelial cell proliferation and angiogenesis.26 Finally, exudate is a physical barrier for cell displacement in the re-epithelization process.26

In summary, exudate from a chronic wound contains plasma components, inflammatory cells, proteins from the inflammatory response, bacteria and components from the bacterial biofilm matrix (Fig. 1). Our hypothesis is that the exudate composition is a biochemical representation of the clinical state of a chronic wound. Therefore, FTIR spectroscopy associated with other clinical parameters could be a useful technique that provides a less-invasive and simple way to represent the clinical state of ulcers and that allows the identification of prognosis/diagnostic markers. For this, the aim of this work was to perform the spectral characterization of exudate from CVLU using FTIR spectroscopy to identify potential healing markers.


image file: c7an01909b-f1.tif
Fig. 1 The production of wound exudate occurs as a result of vasodilation during the inflammatory early stage of healing under the influence of inflammatory mediators. As it could see in the scheme, an exudate from a chronic wound has components from plasma ultrafiltrate. For this, we use as control urine and free-protein serum. In some cases, exudate might receive blood components as plasma compounds, red blood cells (RBC) and white blood cells (WBC) which were used as controls (plasma, RBC + WBC, urea, creatinine, glucose, albumin, phosphates). Once in the wound, plasma coagulate forming a fibrin layer over de wound. To evaluate the contribution of fibrin on exudate ftir spectra, human serum was used. The difference between plasma and serum spectra in Amide I and II windows could show some information about fibrin. Finally, exudate receives contribution from planktonic and biofilm bacterial components. For this, 95% of CVLU isolated bacteria in both phenotypes were used as controls.

Experimental

Ethics

This research protocol was approved and monitored by Independent Medic Ethic Committee from Argentinian Norwest (CIEM-NOA). Patients under observation signed an informed consent before being included in this protocol.

Patients

For the mentioned protocol, 45 patients from Dermatology Service of Nicolas Avellaneda Hospital (San Miguel de Tucuman, Tucuman – Argentina) were selected. Patients with CVLU were diagnosed by venous doppler and clinical criteria.

Inclusion criteria: (a) Ulcer location: lower-third of lower limbs. (b) Both sexes. (c) Age: between 40–80 years. (d) Ulcer size: 20 to 150 cm2. (e) Ulcer evolution time: 1 to 3 years.

Exclusion criteria: Patients with a background of (1) systemic infection, (2) cancer and/or under chemotherapy treatment, (3) autoimmune disease, and (4) drugs abuse were excluded from this study.

As relevant clinical information, patient's clinical association pathologies and ulcer evolution time were analyzed from its clinical records.

Exudate samples

Exudate was obtained by gentle aspiration with a syringe (without a needle and avoiding causing pain and bleeding) from 6 different points of the CVLU and stored at −20 °C until processing.

Spectral contribution controls

In order to evaluate spectral contributions to exudate that come from the plasma ultrafiltrate, the following lyophilized controls were used (Fig. 1):

Serum (n = 8): Obtained by whole blood extraction from random patients. Sera were left to clot for 15 minutes and then centrifuged for 10 min at 3000 rpm.

Plasma (n = 8): Obtained by whole blood extraction from random patients on sodium citrate 1.2% w/v (ratio: 9/1) and centrifuged for 10 min at 3000 rpm.

Free-protein serum (n = 8): This control is useful to find if there are protein contributions to exudate spectra that did not come from plasma, analyzing specifically in the protein spectral regions. Polson et al. protocol was followed to obtain this free-protein serum.27 A serum aliquot was separated and then treated with absolute ethanol 99.5% v/v (Cicarelli) (1/0.5), incubated at −20 °C for 12 h and then centrifuged at 8000 rpm for 20 minutes. This process was repeated twice to ensure serum deproteinization and corroborated with UV spectroscopy (200–400 nm)28 and the Bradford method.29

Urine (n = 8): Urine is a plasma ultrafiltrate and for this reason it could be a useful control for exudate study as a free-protein control (Fig. 1). Urine samples were taken after day-first urine from 8 volunteer human subjects in order to reduce the amount of filtered proteins to the maximum. Urine samples come from 8 different human volunteers between 30–40 years old with no kidney disease history, hepatic disease or use of chronic medication to ensure the correct glomerular function. Free-cell urines were obtained by centrifugation at 3000 rpm for 10 min.

Blood cells control (n = 8) was used to analyze the cellular contribution from inflammatory response (white blood cells – WBC) and bleeding (red blood cells – RBC) to exudate (Fig. 1). To obtain this control, a whole blood anticoagulated (citrate 1.2% w/v) aliquot was separated and centrifuged at 3000 rpm for 10 min, then plasma was separated and the remaining cells (WBC + RBC) were washed with saline three times. Finally, the cells were re-suspended in saline and stored at 4 °C until their processing.

Other serum controls: Different controls were carried out to analyze the individual contributions of most important seric molecules (Fig. 1). Glucose (Cicarelli-Argentina), urea (Cicarelli-Argentina), creatinine (Anedra-Argentina) and inorganic H2PO41−/HPO42− mix (Cicarelli-Argentina), and human albumin (Sigma-Aldrich-USA) were used as individual drug controls.

To corroborate the protein amount and confirm the origin of the protein contributions to spectra, two assays for protein determination were performed over albumin, urea, creatinine, urine, free-protein serum and serum controls: UV spectra obtained at 200–400 nm (ref. 26) and the Bradford method.27

Bacteria

To find bacterial contributions to the exudate FTIR spectra (Fig. 1), strains isolated from CVLU were studied in their planktonic and biofilm forms. Selected strains were isolated from CVLU exudate samples by conventional methods and represent 95% of the aerobic isolations.16,30–32 Isolated Gram-positive bacteria were Staphylococcus aureus, methicillin resistant S. aureus (MRSA), S. haemolyticus, coagulase negative Staphylococcus (CNS), beta-hemolytic Streptococcus and Enterococcus faecalis. Isolated Gram-negative bacteria were: Pseudomonas aeruginosa, Pseudomonas sp, Escherichia coli, Serratia marscecens, Proteus mirabilis, Enterobacter aerogenes, Enterobacter sp, Klebsiella pneumoniae, Burkholderia cepacia, Providencia sp and Citrobacter sp. All bacteria were stored at −20 °C in BHI media + glycerol (30%).

Planktonic form: Each strain was activated at room temperature for 30 min, cultured in BHI broth and then incubated for 6 h at 37 °C. Cultures were centrifuged at 8000 rpm for 10 min and planktonic cell pellets were washed 3 times (saline) to remove the culture medium. Planktonic pellets were lyophilized before their spectroscopic study.

Biofilm formation: Each strain was activated at room temperature for 30 min, cultured in BHI broth or BHI broth ((plus 5% v/v) human serum for nutritionally highly demanding bacteria) (1/10 v/v) and then incubated at 37 °C until the biofilm formation (12 to 24 h depending on the strain). In some cases, bacteria were stressed to allow biofilm formation (nutritional stress, UV radiation, thermic stress). Cultures were centrifuged at 3000 rpm for 10 min (to obtain mainly a biofilm pellet). Biofilm pellets were washed 3 times (saline) to remove the culture medium and planktonic bacteria. Biofilm pellets were lyophilized before their spectroscopic study.

FTIR spectroscopy

To collect FTIR spectra, a PerkinElmer GX 1 spectrophotometer was used. Exudate samples and controls were processed as liquid samples, 5 μl of exudate sample and controls were dried under a N2 flow and vacuum over AgCl circular optical windows. Each planktonic and biofilm bacteria was processed as solid samples twice on KBr pellets of spectroscopic grade (1[thin space (1/6-em)]:[thin space (1/6-em)]20). Spectra were collected with 64 scans and 4 cm−1 of resolution in the range of mid-infrared 4000 cm−1–400 cm−1. For spectral pre-processing smoothing, baseline correction and normalization with amide I band were used. Pre-processing is useful to compensate for differences in the sample quantity or a different optical pathlength.7,32
Infrared region. According to the vibration frequency of the main biomolecule bonds,2,7,33,34 different spectral windows were selected according to the main bonds characteristic of each biomolecule: W1: CH3 and >CH2 of lipids (2800–3000 cm−1); W2: ester bonds (1770–1720 cm−1); W3: amide I (1700–1600 cm−1); W4: amide II (1600–1480 cm−1); W5: phosphates of nucleic acids (1270–1190 cm−1); W6: carbohydrate bonds of polysaccharides (1190–900 cm−1). The mixed region (1480–1280 cm−1), unspecific region (4000–3000 cm−1) and fingerprint region (900–400 cm−1) were not taken into account for this study (Fig. 2). Table 1 shows the proposed assignments for different biomolecules studied.
image file: c7an01909b-f2.tif
Fig. 2 Selected spectral windows for each biomolecule marked on a typical exudate spectrum. The same windows were used for spectral contribution controls analysis.
Table 1 Proposed vibrational modes at different frequencies to define work regions (windows) in this study.1–3,5,7,32,33 The primary source proposed are biomolecules which present high particular bonds amount that present absorbance at each window. That allow define each region as a windows where a particular biomolecule concentration could be measured
Window Denomination Wavenumber (cm−1) Proposed vibrational mode Proposed primary source
W1 CH3; CH2 3000–2800 C–H asymmetric and symmetric stretch of >CH2 and CH3 present on fatty acids and lipids Lipids, membrane phospolipids.
W2 Ester bonds 1770–1720 >C[double bond, length as m-dash]O stretch of ester bonds in fatty acids Lipids, membrane phospolipids.
W3 Amide I 1715–1600 >C[double bond, length as m-dash]O stretch, C–N stretch, CCN deformation in peptide bonds Proteins and peptides
W4 Amide II 1600–1480 NH bend, C–N stretch, CO bend, N–C stretch Proteins and peptides
W5 Phosphate bonds 1270–1200 >PO2 stretch in RNA/DNA or NH bend, C–C stretch, C–N stretch, CO bend (Amide III) Nucleic acids and proteins.
W6 Carbohydrates bonds 1190–900 C–O, C–C stretch, C–O–H, C–O–C deformation of carbohydrates or >PO2sym. stretch of phosphodiester group in nucleic acids Carbohydrates, polysaccharides and nucleic acids


Spectral area. Spectral area was measured by OMNIC 8.0 software in all standardized biomolecule windows of each normalized spectrum. Total spectral area corresponds to the sum of the individual area values. From these measurements, different ratios were calculated and percentages of biomolecules shown on spectra were estimated.
Second derivative. Second derivative Savitzky–Golay (SG) (9 points and order 3) were obtained by OMNIC 8.0 software for all spectra. Each standardized biomolecule window was analyzed to find peaks in its corresponding region. As selection criteria 100% of sensitivity and a threshold of 0.010 were used for peak selection (software parameters). Before second derivative obtaining, the original absorbance spectra were previously converted to transmittance units in order to match the second derivative peaks with the original spectrum bands (software requirement for peak selection).

Statistics

Statistical significance was evaluated using the Mann–Whitney–Wilcoxon U test for non-parametrical variables. Data analysis was performed with GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA).

Results and discussion

Exudate, plasma, serum, free-protein serum and urine spectral areas

In this study, the relative composition of each biological polymer in exudates and controls (serum, plasma, free-protein serum, urine, blood cells and other related controls) (Fig. 3a–l) was studied by measurement of spectral areas and ratios between them. Also it was found that each analyzed sample by FTIR (exudates and controls) shows a unique relative composition and ratio. This could be used to identify sample types (exudates, plasmas, serum, urine) (Fig. 4). Table 2 shows the relative composition of each exudate.
image file: c7an01909b-f3.tif
Fig. 3 Typical FTIR spectra for different samples and controls at mid-infrared frequencies (4000 cm−1–400 cm−1). a. Serum; b. plasma; c. free-protein serum; d. urine; e. cells (WBC + RBC) control; f. exudate; g. albumin; h. creatinine; i. glucose; j. urea; k. phosphate mixture; l. absolute ethanol.

image file: c7an01909b-f4.tif
Fig. 4 Mean FTIR spectral areas measured in each window for different samples and controls analyzed. Frequency regions for each window were determined according specific biomolecules bonds (Table 1).
Table 2 FTIR spectral characterization of exudates. The observed values correspond to relative spectral areas in each window and therefore represent exudate biopolymers relative composition
Exudate W1 W2 W3 W4 W5 W6
001 11.21 0.58 22.18 12.19 2.29 14.81
002 13.50 0.00 23.56 11.67 3.37 13.63
003 11.70 0.00 27.12 10.00 1.50 16.27
004 12.97 0.00 32.90 15.00 3.31 18.16
005 19.66 1.75 28.02 16.17 2.90 17.82
006 16.12 0.83 29.76 15.24 3.71 24.66
007 20.07 1.76 34.26 14.82 3.95 28.06
008 18.60 1.53 34.36 14.15 4.13 29.37
009 9.59 0.00 36.95 17.42 1.85 5.68
010 8.61 0.00 35.14 15.83 1.54 4.50
011 14.88 0.23 36.02 17.70 2.61 16.84
012 32.68 4.81 36.60 17.43 4.37 25.49
013 16.99 0.00 37.22 19.65 2.39 13.34
014 11.78 0.02 38.12 16.93 3.31 22.36
015 19.69 0.64 28.68 14.63 2.78 17.02
016 26.54 3.50 33.72 18.72 2.76 12.71
017 10.37 0.00 49.91 22.36 1.83 4.88
018 7.77 0.04 29.77 16.01 1.61 9.07
019 19.84 0.15 32.69 15.91 5.90 42.69
020 14.25 0.00 33.23 17.01 3.61 22.10
021 17.36 0.36 36.55 19.44 2.99 21.10
022 17.92 0.16 39.36 18.69 3.92 20.08
023 12.84 0.01 36.39 17.13 2.87 16.66
024 12.01 0.37 26.85 11.67 0.95 14.60
025 7.97 0.12 33.30 16.95 1.59 8.09
026 15.97 0.15 38.86 20.65 2.96 21.05
027 10.74 0.00 35.82 16.84 2.28 26.92
028 9.75 0.05 35.51 16.51 1.35 17.98
029 18.99 0.55 37.06 15.54 5.11 44.04
030 12.19 0.00 39.63 18.19 1.86 10.47
031 10.21 0.00 39.11 17.10 1.22 9.64
032 8.41 0.00 40.35 18.98 1.96 38.19
033 20.10 0.00 34.04 11.59 2.42 49.04
034 9.26 0.00 27.40 13.17 0.97 10.98
035 10.89 0.05 35.85 17.67 2.85 15.27
036 6.67 0.00 35.11 17.32 1.32 6.38
037 8.60 0.09 35.45 13.34 2.09 15.94
038 10.57 0.05 32.84 12.97 1.17 24.31
039 10.14 0.00 35.38 17.76 2.21 27.06
040 7.64 0.00 38.39 21.18 1.75 5.09
041 9.45 0.02 42.22 20.88 2.91 13.17
042 17.02 0.33 36.76 17.06 3.78 29.22
043 9.44 0.09 36.24 16.67 1.62 22.28
044 26.60 2.41 26.04 7.17 1.97 42.22
045 14.62 0.82 38.72 18.44 4.77 35.42
 
Mean 14.05 0.48 34.52 16.26 2.63 20.10
SD 5.64 0.98 5.13 3.05 1.15 11.06
MIN 6.67 0.00 22.18 7.17 0.95 4.50
MAX 32.68 4.81 49.91 22.36 5.90 49.04


CH3/CH2 window (lipids). These areas are mainly determined by the C–H asymmetric and symmetric stretching of >CH2 and CH3 groups that are typically present in fatty acids and lipids in biological samples (Table 1). There are no significant differences between the spectral areas of exudate and plasma, serum, free-protein serum and cells which indicates a similar lipid concentration (Fig. 4). In these samples, fatty acids and lipids are possibly represented by membrane phospholipids from prokaryotic and eukaryotic cells and/or from VLDL, LDL, HDL and chylomicrons.35 In exudates, we expect contributions mainly from cell membrane lipids, which was demonstrated by the great similarity of areas between exudates and cells (Fig. 4). Therefore, exudate cellularity could be estimated from this window area. Logically, urines do not have absorbance in this region, not only because they are free-cell urines but also because they are free from lipoproteins.

Oppositely, albumin shows the C–H asymmetric and symmetric stretching of >CH2 and CH3 from its hydrocarbon chain.

Ester bonds window (lipids). This area is mainly determined by the >C[double bond, length as m-dash]O stretching of ester bonds in fatty acids (Table 1). Exudates and free-protein serum were the only samples that showed this spectral band (Fig. 4). In the case of exudates, the presence of this band (and the associated peaks in the second derivative) could represent the membrane phospholipid concentration in the sample. Moreover, free-protein serum controls exhibit absorbance, which may be due to ester bond formation by the alcohol used during the deproteinization method.
Amide I and amide II windows (proteins). Amide I areas are mainly determined by the >C[double bond, length as m-dash]O stretching of the peptidic bond of proteins and peptides, followed by C–N swinging and other vibrations of secondary protein structure components. Amide II areas are mainly determined by vibrations of the NH bend, C–N stretch, CO bend and N–C stretch (Table 1).

The protein absence of free-protein controls, like free-protein serum and urine, was demonstrated by UV spectra (Fig. 5) and the Bradford method (data not shown). These samples show lower amide I areas with respect to exudate, serum and plasma (ρ < 0.001). However, despite being free-protein samples, they still have absorbance in the amide I window (Fig. 4). This might be caused by the contribution of the C[double bond, length as m-dash]O stretching and N–H stretching and the deformation of urea,36 strong C[double bond, length as m-dash]O stretching, C–C–N bending of creatinine bonds37 as urea and creatinine spectra are also shown (Fig. 3h and j).


image file: c7an01909b-f5.tif
Fig. 5 UV spectra obtained from several samples to analyze protein concentration at 280 nm. Null absorbance at 280 nm for free-protein serum was observed. Despite that urine does not have protein concentration, absorbance at 280 nm could be explained by absorbance of creatinine at this frequency.

It was previously demonstrated that the wound fluid protein concentration (measured by biochemical methods) is lower than the serum protein concentration.18,21 However, there were no significant differences between amide I areas of exudate, serum and plasma (Fig. 4). As all these samples have similar concentrations of urea and creatinine,18,21 this would indicate also a similar protein concentration which is not correct. This may be because in the amide I region the contributions of the inflammatory, bacterial and serum proteins all together to exudates were detected. This compensates for the difference detected by biochemical methods that only measure inflammatory and seric proteins.18,21

Amide II areas represent the real protein content of the samples, because free-protein serum and urine show null or minimum absorbance and serum and plasma were significantly higher than exudate (ρ < 0.001) as expected (Fig. 4).

Phosphate window (nucleic acids). In this window, areas are mainly determined by >PO2 stretch absorbance present in RNA and DNA (Table 1). However, in this region the vibrations of NH bending, C–C stretching, C–N stretching and CO bending of Amide III also may be present.2

Urine and free-protein serum show null absorbance in this region, which is logical as both samples are DNA/RNA/protein free (Fig. 4 – phosphate bonds). In contrast, areas observed in serum and plasma could be caused by proteins while the observed areas in cells and exudates could be a result of the sum of nucleic acids and proteins. Taking into account that: (1) the exudate protein content is lower than the serum protein content (Fig. 4 – Amide II);18,21 (2) there is no significant difference between phosphate bonds as in serum and exudate, and (3) phosphate areas in cells are significantly lower than phosphate areas in exudates (ρ < 0.001); we could assume that the difference between the phosphate areas from exudates and cells is mainly determined by nucleic acids indirectly related to the exudate cellularity (Fig. 4 – Phosphate bonds).

Carbohydrate bonds (polysaccharides). In this window, areas are mainly determined by C–O, C–C stretching, C–O–H, C–O–C deformation of carbohydrates or C–OH stretching of serine, threonine, and tyrosine in proteins (Table 1).

In serum and plasma, area values probably came from the vibrational modes of glycoproteins, glucose and other sugars. Cells presented absorbance because of the membrane glycoproteins’ presence. Albumin has absorbance in this window because of the C–OH stretching and vibrational modes of serine, threonine and tyrosine.2 In exudates, area values probably came from the vibrational modes of cellular glycoproteins, glucose, seric glycoproteins, lipopolysaccharides from planktonic bacteria and exopolysaccharides from the bacterial biofilm matrix. There is an important variability in the polysaccharide concentration among all samples which is demonstrated by the elevated standard deviation (SD) in the polysaccharide area from exudate samples (Fig. 4 – Carbohydrate bonds). Taking into account that all controls present low SD we could assume that the elevated SD in exudates may be due to different biofilm matrix exopolysaccharides’ contribution from infecting bacteria.23,33 Because of this polysaccharide areas in exudates could indirectly represent its biofilm load.

Free-protein serum carbohydrate areas were significantly higher than exudate areas (ρ < 0.001). This may be due to spectral contributions of the remnant alcohol (C–OH) from the deproteinization method (Fig. 3l and 4).

Spectral areas of bacteria

We analyzed 95% of the aerobic clinical isolates16 from CVLU exudates. Each strain showed a unique relative composition for planktonic and biofilm phenotypes (Table 3). This could be useful to identify bacteria in the phenotypic-ulcer state. This also allows differentiation of whether bacteria are in biofilm or planktonic phenotype, which is unlikely by conventional methods. Besides, as mentioned above, a broad variability among polysaccharide areas for all bacteria spectra was observed. This could be as a result of the different exopolysaccharide composition in each case.
Table 3 FTIR spectral characterization of bacteria. The observed values correspond to relative spectral areas in each window and therefore represent bacterial biopolymers relative composition in planktonic and biofilm phenotype. Also, the table shows second derivative peaks that were present only in such strains
  Bacteria W1 W3 W4 W5 W6 2nd derivative peaks
Planktonic phenotype Staphylococcus haemolyticcus 10.22 65.80 1.35 17.12 43.73 1750, 1095
Staphylococcus aureus 22.30 42.22 6.77 21.52 97.23 1259, 1239, 1090
MRSA 17.11 55.06 9.02 11.66 54.63 968
Enterococcus faecalis 12.76 48.41 14.02 18.00 40.53 1719, 1614, 1546, 1074
Enterococcus faecalis 25.52 56.20 7.09 11.27 65.84 1719, 1090
Beta-hemolytic Streptococcus 7.06 45.64 10.08 3.70 42.39 1695, 1545, 1230, 1078, 1015, 970
Proteus mirabilis 13.69 47.82 12.77 8.09 30.82 1060
Proteus mirabilis 12.97 49.84 16.28 6.56 30.02
Enterobacter sp. 12.45 58.33 16.7 8.34 31.88
Enterobacter aerogenes 16.43 56.51 10.65 8.60 56.45
Pseudomona sp. 14.93 53.93 13.28 9.77 53.02 1731, 1227, 1177, 1127
Pseudomona sp. 12.82 50.22 10.18 4.70 37.13 1731, 1227, 1097
Pseudomona. aeruginosa 25.50 50.20 3.00 3.90 44.70 1665
Providencia sp. 8.91 45.65 9.96 4.68 20.31
Citrobacter sp. 13.75 49.88 13.85 5.63 36.25 1716
Klebsiella pneumoniae 13.45 45.30 12.02 5.53 40.96 1641
Klebsiella pneumoniae 16.74 53.97 8.92 6.90 59.65 1641
Serratia marcescens 17.29 55.37 15.08 8.90 36.78 2874
Escherichia coli 9.79 48.46 15.66 4.89 23.08 1236, 1120
Escherichia coli 14.98 33.81 14.99 5.45 36.82 1236, 1120
Burkholderia cepacia 15.26 56.20 18.16 7.97 29.43
 
Biofilm phenotype Staphylococcus haemolyticcus 12.95 56.15 17.60 8.44 33.67
Staphylococcus aureus 15.09 56.79 15.04 9.36 47.67 2744, 984
Beta-hemolytic Streptococcus 14.05 61.75 13.69 7.44 52.79 969
Beta-hemolytic Streptococcus 11.12 34.2 13.25 6.57 45.63 969
Enterococcus faecalis 13.08 45.26 12.02 7.10 41.70 1634, 1212
Enterococcus faecalis 20.31 49.39 5.45 10.92 95.41 1212
MRSA 13.78 59.48 12.17 8.01 50.41
MR-CNS 9.90 34.04 11.36 5.63 44.37 1075
CNS 10.04 61.39 8.58 11.83 41.58 971
Proteus mirabilis 13.08 58.88 15.17 8.00 30.20 1511, 1637, 1619, 1238, 1089
Proteus mirabilis 13.07 47.27 14.23 4.415 27.34 1511, 1637, 1619, 1238, 922
Enterobacter sp 14.89 46.87 16.23 8.23 24.29
Enterobacter aerogenes 16.47 48.02 13.50 11.14 77.33
Pseudomona aeruginosa 17.00 43.80 11.30 6.90 27.20 1085
Pseudomona sp. 14.33 45.83 16.60 5.74 28.29 1223
Pseudomona sp. 16.55 55.84 17.32 7.77 34.7
Citrobacter sp. 10.24 47.99 10.77 5.20 26.76
Klebsiella penumoniae 15.48 47.55 12.19 8.39 49.68 2873, 1163, 1104, 1068, 990
Klebsiella penumoniae 16.97 49.61 11.50 7.70 57.43 2873
Escherichia coli 11.55 50.5 16.40 6.54 30.43
Burkholderia cepacia 12.53 47.76 15.5 5.39 25.25


Peaks

A deep study of the peaks founded in 2nd derivative spectra from exudate samples, controls and bacteria in both phenotypes was performed. Here we only show the typical sample peaks that could have clinical significance.

In the CH3/CH2 region (W1) a characteristic peak at ∼2933 cm−1 was found in exudate spectra (100%) and in blood cell spectra (100%). This peak could represent the presence of cellular membrane phospholipids from inflammatory cells since this peak is absent in bacteria and controls.

In the ester bond region (W2) a peak between 1716–1713 cm−1 was found in exudates (75%) and bacteria in both biofilm (100%) and planktonic (83%) phenotypes. Since this peak is absent in blood cells spectra and other controls, it could represent membrane phospolipids from bacterial cells.

In the amide I region (W3), 100% of plasma and exudate samples showed a peak at 1690 cm−1. Furthermore, 100% of serum samples present a peak at 1695 cm−1 with lower absorbance. This displacement and lower absorbance could be owing to fibrinogen that is the only proteic difference between plasma and serum (Fig. 6). Therefore, this peak could be useful to measure fibrin amounts in exudates.


image file: c7an01909b-f6.tif
Fig. 6 Savitzky–Golay 2nd derivative from spectra of serum, plasma, exudate and bacteria in planktonic (p) and biofilm (b) phenotypes between 1800–1600 cm−1.

In all bacteria spectra (planktonic and biofilm), peaks between 1633–1629 cm−1 and 1623–1616 cm−1 were the ones with higher absorbance than other amide I peaks (Fig. 6). Besides, a specific peak between 1682 and 1680 cm−1 was founded only in exudate samples (100%). Because this peak is absent in plasma, serum and bacteria, it would represent tissue pro-inflammatory proteins. Among them we can find proteases as serine proteinase, cysteine proteinase, aspartic proteinase and matrix metalloproteinases (MMPs).12,17,19 If it is demonstrated that this peak belongs to exudate proteases, it would be extremely useful for the ulcers prognosis, as there is a correlation between elevated levels of proteases and delayed healing.12,25,26

In the amide II region (W4) a peak at 1497 cm−1 was found in 100% of exudate and serum controls although we couldn't find a possible assignment for it.

In the phosphate bonds region (W5), a specific peak between 1262 and 1260 cm−1 only in 100% of exudates (with an important absorbance) was found. Hence, it could be another representative peak for proteases as was previously assigned to Amide III vibrations (Table 1). Planktonic bacteria present a peak between 1244 and 1242 cm−1 and eukaryotic cells present a peak between 1236 and 1234 cm−1. These peaks represent a DNA A-form marker for antisymmetric PO2 stretch.37 Therefore, these peaks could represent prokaryotic/eukaryotic load in the sample as both are present in exudates.

In the carbohydrates bonds region (W6) an extraordinary variability of peaks was founded. There are only a few peaks that were sample-characteristic as 1171–1174 cm−1 for exudate (100%) and 1097–1093 cm−1 for biofilm and planktonic bacteria (100%). The rest of the founded peaks might represent the variability produced by biofilm matrix exopolysaccharides and glycoproteins in exudates and glycoproteins in plasma and serum.

Conclusion

FTIR spectroscopy allows us to identify sample types (exudates, plasmas, serum, urine, planktonic bacteria, biofilm bacteria) as each one presents a unique relative composition and ratios range. Also, this technique could be useful to identify bacteria in the phenotypic-ulcer state and allows us to differentiate if bacteria are in the biofilm or planktonic form which is unlikely by conventional methods.

Because the measured areas or the located peaks are concentration-dependent, this method could serve to study several parameters in exudate as follows:

(1) Exudate cellularity.

(a) Total cellularity could be estimated from the CH3/CH2 window area.

(b) Inflammatory cells load could be estimated from the ester bond window area or by measuring 2933 cm−1 and/or 1236–1234 cm−1 peak areas from the 2nd derivative (SG).

(c) Bacterial load could be estimated by measuring 1716–1713 cm−1 and/or 1244–1242 cm−1 peak areas from the 2nd derivative (SG).

(2) Exudate total protein content

(a) In complex human fluid samples like exudates, urine, serum or plasma is advisable to use amide II areas to estimate the total protein content.

(d) The fibrin amount could be estimated by measuring the 1690 cm−1 peak area from the 2nd derivative (SG).

(b) Inflammatory proteins could be estimated by measuring 1682–1680 cm−1 and/or 1262–1260 cm−1 peak areas from the 2nd derivative (SG).

(3) Exudate biofilm load could be indirectly estimated by measuring the carbohydrate bond area.

All of these exudate parameters could be useful to evaluate patient evolution as cells and proteins from inflammatory response, fibrin and planktonic or biofilm bacterial load represent critical negative markers for wound healing. Hence, FTIR spectroscopy could be a useful technique that provides a less-invasive and simple way to represent the clinical state of the wound.

In the future, the use of other spectral contribution controls could allow the identification of more specific markers in exudate. For example, hemoglobin as a bleeding marker, purified specific phospholipids from eukaryotic membranes as an inflammatory cellularity marker, lipopolysaccharides and peptidoglycan as a bacterial cellularity marker, matrix metalloproteinases (MMP-2, MMP-8, MMP-9) as protease activity markers and different exopolysaccharides from the bacterial biofilm matrix (i.e. alginate) as specific biofilm infection markers.

Conflicts of interest

The authors declare no competing financial interest.

Acknowledgements

This work was supported by grants: BID 3664 PICT 2014, BID 2530 PICT 2014 and D-TEC 0022/2013 from the National Agency for Scientific and Technological Promotion, Argentina.

References

  1. K. Gajjar, J. Trevisan, G. Owens, P. J. Keating, N. J. Wood, H. F. Stringfellow, P. L. MartinHirschb and F. L. Martin, Analyst, 2013, 138, 3917–3926 RSC.
  2. M. J. Baker, E. Gazi, M. D. Brown, J. H. Shanks, P. Gardner and M. E. Sesto Cabral, Br. J. Cancer, 2008, 99(11), 1859–1866 CrossRef CAS PubMed.
  3. B. Singh, R. Gautam, S. Kumar, B. N. Vinay Kumar, U. Nongthomba, D. Nandi, G. Mukherjee, V. Santosh, K. Somasundaram and S. Umapathy, Curr. Sci., 2012, 102(2), 232–244 CAS.
  4. C. Petibois and B. Desbat, Trends Biotechnol., 2010, 28(10), 495–500 CrossRef CAS PubMed.
  5. P. D. Lewis, K. E. Lewis, R. Ghosal, S. Bayliss, A. J. Lloyd, J. Wills, R. Godfrey, P. Kloer and L. Aj Mur, BMC Cancer, 2010, 10(1), 640–670 CrossRef CAS PubMed.
  6. J. Ollesch, S. L. Drees, H. M. Heise, T. Behrens, T. Brüning and K. Gerwert, Analyst, 2013, 138(14), 4092–4102 RSC.
  7. M. J. Baker, J. Trevisan, P. Bassan, R. Bhargava, H. J. Butler, K. M. Dorling, P. R. Fielden, S. W. Fogarty, N. J. Fullwood, K. A. Heys, C. Hughes, P. Lasch, P. L. Martin-Hirsch, B. Obinaju, G. D. Sockalingum, J. Sulé-Suso, R. J. Strong, M. J. Walsh, B. R. Wood, P. Gardner and F. L. Martin, Nat. Protoc., 2014, 9(8), 1771–1791 CrossRef CAS PubMed.
  8. R. K. Sahu and S. Mordechai, Future Oncol., 2005, 1(5), 635–647 CrossRef CAS PubMed.
  9. R. Serra, R. Grande, G. Buffone, V. Molinari, P. Perri, A. Perri, B. Amato, M. Colosimo and S. de Franciscis, Int. Wound J., 2016, 13(1), 53–58 CrossRef PubMed.
  10. G. A. Rahman, I. A. Adigun and A. Fadeyi, Ann. Afr. Med., 2010, 9, 1–4 CrossRef CAS PubMed.
  11. G. Lazarus, M. Fran Valle, M. Malas, U. Qazi, N. M. Maruthur, D. Doggett, O. A. Fawole, E. B. Bass and J. Zenilman, Wound Repair Regen., 2014, 22(1), 34–42 CrossRef PubMed.
  12. R. Serra, G. Buffone, D. Falcone, V. Molinari, M. Scaramuzzino, L. Gallelli and S. de Franciscis, Wound Repair Regen., 2013, 21(3), 395–401 CrossRef PubMed.
  13. H. Edwards, K. Finlayson, H. Skerman, K. Alexander, C. Miaskowski, B. Aouizerat and M Gibb, Identification of symptom clusters in patients with chronic venous leg ulcers, J. Pain Symptom Manage., 2014, 47(5), 867–75 CrossRef PubMed.
  14. R. T. Emalberhardt and J. D. Raffetto, Circulation, 2005, 111(18), 2398–2409 CrossRef PubMed.
  15. K. Gjødsbøl, J. J. Christensen, T. Karlsmark, B. Jørgensen, B. M. Klein and K. Krogfelt, Int. Wound J., 2006, 3(3), 225–231 CrossRef PubMed.
  16. S. V. Agale, Ulcers, 2013, 2013, 1–9 CrossRef.
  17. A. D. Widgerow, Wound Repair Regen., 2011, 19(3), 287–291 CrossRef PubMed.
  18. N. J. Trengove, S. R. Langton and M. C. Stacey, Wound Repair Regen., 1996, 4(2), 234–239 CAS.
  19. K. F. Cutting, Br. J. Community Nurs., 2003, 8(3), 4–9 CrossRef.
  20. A. J. Signer and R. A. Clark, N. Engl. J. Med., 1999, 341, 738–746 CrossRef PubMed.
  21. T. J. James, M. Hughes, G. W. Cherry and R. P. Taylor, Wound Repair Regen., 2000, 8(4), 264–269 CrossRef CAS PubMed.
  22. D. Metcalf and P. Bowler, Burns Trauma, 2013, 1(1), 5–12 CrossRef PubMed.
  23. I. W. Sutherland, Microbiology, 2001, 147(1), 3–9 CrossRef CAS PubMed.
  24. V. Papayannopoulos and A. Zychlinsky, Trends Immunol., 2009, 30(11), 513–521 CrossRef CAS PubMed.
  25. J. C. McDaniel, S. Roy and T. Wilgus, Wound Repair Regen., 2013, 21(3), 339–351 CrossRef PubMed.
  26. B. Amato, G. Coretti, R. Compagna, M. Amato, G. Buffone, D. Gigliotti, R. Grande, R. Serra and S. de Franciscis, Int. Wound J., 2015, 12(6), 641–645 CrossRef PubMed.
  27. C. Polson, P. Sarkar, B. Incledon, V. Raguvaran and R. Grant, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 2003, 785(2), 263–275 CrossRef CAS.
  28. C. N. Pace, F. Vajdos, L. Fee, G. Grimsley and T. Gray, Protein Sci., 1995, 4(11), 2411–2423 CrossRef CAS PubMed.
  29. W. Gebauer, ELS, 2002, 2–4 Search PubMed.
  30. K. Kirketerp-Møller, P. Ø. Jensen, M. Fazli, K. G. Madsen, J. Pedersen, C. Moser, T. Tolker-Nielsen, N. Høiby, M. Givskov and T. Bjarnsholt, J. Clin. Microbiol., 2008, 46(8), 2717–2722 CrossRef PubMed.
  31. D. D. Rhoads, R. D. Wolcott, Y. Sun and S. E. Dowd, Int. J. Mol. Sci., 2012, 13(3), 2535–2550 CrossRef CAS PubMed.
  32. P. Lasch, Chemom. Intell. Lab. Syst., 2012, 117, 100–114 CrossRef CAS.
  33. A. Bosch, D. Serra, C. Prieto, J. Schmitt, D. Naumann and O. Yantorno, Appl. Microbiol. Biotechnol., 2006, 71(5), 736–747 CrossRef CAS PubMed.
  34. D. Naumann and P. Lasch, Biomedical Spectroscopy, Encyclopedia of analytical chemistry, Wiley J & Sons, 2015 Search PubMed.
  35. K. Liu, R. A. Shaw, A. Man, T. C. Dembinski and H. H. Mantsch, Clin. Chem., 2002, 48(3), 499–506 CAS.
  36. M. Khanmohammadi, K. Ghasemi, A. B. Garmarudi and M. Ramin, Spectrochim. Acta, Part A, 2014 Search PubMed.
  37. M. Banyay, M. Sarkar and A. Graslund, Biophys. Chem., 2003, 104, 477–488 CrossRef CAS PubMed.

This journal is © The Royal Society of Chemistry 2018